Our leadership is deeply embedded in the industry and supported by an Advisory Board of experts from every sector that we serve.
Staying at the cutting edge of every change in the market allows us to deliver the right candidates for your business and provide invaluable counsel no matter how unique your needs.
Founded in 2000, Slone Partners is a premier executive search firm that specializes in recruitment for companies focused in biotechnology, pharma services, life science tools, diagnostics, genomics, clinical services, medical devices, data and analytics, and food sciences.
Executive search firm Slone Partners has named Leslie Loveless as its new chief executive officer. She succeeds Adam Slone, who founded the firm in 2000. Mr. Slone will remain engaged with the firm, focusing specifically on strategy, finance, mergers and acquisitions, advisement and business development in Boston and California. Ms. Loveless joined Slone Partners in 2007
Executive recruiters Slone Partners has placed Dr. Richard Bender as chief medical officer at Signal Genetics, a commercial stage, molecular genetics diagnostic company located in Little Rock, AR. Dr. Bender has spent 25 years in clinical practice the majority spent serving as the medical director for oncology / hematology for Kaiser Permanente in San Diego. In 2002 he
Executive recruiters Slone Partners has placed Nadia Altomare as president of North America at Abcodia, a specialist company engaged in the development of tests for early detection of cancer. As president, Ms. Altomare will develop and implement the strategic business plan for U.S. operations, launch the company’s first early cancer detection product in the U.S. — the ROCA test —
Thought Leadership
Elevating Executive Presence: A Blueprint for Life Sciences and Biotech Leaders
What’s Next in Precision Medicine: Leadership Challenges and Opportunities
Full-Time vs. Fractional Talent: What’s the Best Fit for Your Organization?
Fractional Talent On Demand: The Slone Partners Difference
Life Sciences Leadership, Redefined: What Boards are Looking for in 2025